Roche Holding AG (OTCMKTS:RHHBY) Short Interest Up 117.4% in February

Roche Holding AG (OTCMKTS:RHHBY) saw a large increase in short interest in February. As of February 27th, there was short interest totaling 6,049,045 shares, an increase of 117.4% from the February 12th total of 2,782,461 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average trading volume of 3,806,703 shares, the days-to-cover ratio is currently 1.6 days. Based on an average trading volume of 3,806,703 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.1% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on RHHBY shares. The Goldman Sachs Group upgraded shares of Roche from a “sell” rating to a “hold” rating in a research report on Thursday, January 15th. Citigroup began coverage on Roche in a research report on Tuesday, January 27th. They set a “buy” rating for the company. TD Cowen reissued a “hold” rating on shares of Roche in a report on Tuesday, February 10th. Zacks Research raised Roche from a “strong sell” rating to a “hold” rating in a research note on Monday, January 5th. Finally, Wolfe Research reiterated an “outperform” rating on shares of Roche in a research report on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Roche has an average rating of “Hold” and an average target price of $57.00.

Roche Trading Down 3.5%

Shares of OTCMKTS:RHHBY opened at $50.12 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. Roche has a 12 month low of $34.75 and a 12 month high of $60.85. The stock’s 50 day moving average price is $56.04 and its 200 day moving average price is $49.00.

Institutional Trading of Roche

A number of hedge funds and other institutional investors have recently modified their holdings of RHHBY. Boston Common Asset Management LLC lifted its holdings in shares of Roche by 1.9% in the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock valued at $15,049,000 after buying an additional 6,720 shares during the period. Altrius Capital Management Inc grew its holdings in Roche by 4.0% during the third quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock worth $8,290,000 after acquiring an additional 7,659 shares during the period. Bard Financial Services Inc. raised its position in Roche by 1.3% in the third quarter. Bard Financial Services Inc. now owns 138,650 shares of the company’s stock worth $5,797,000 after acquiring an additional 1,800 shares in the last quarter. Rhumbline Advisers raised its position in Roche by 1.1% in the second quarter. Rhumbline Advisers now owns 108,480 shares of the company’s stock worth $4,422,000 after acquiring an additional 1,228 shares in the last quarter. Finally, Meritage Portfolio Management acquired a new stake in Roche in the 4th quarter valued at about $4,372,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.